Products
Garadacimab Biosimilar Monoclonal Antibody (Factor XII) for Research
Pre-Made Garadacimab biosimilar, Whole mAb, Anti-F12 Antibody: Anti-HAE3/HAEX/HAF therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-233-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Garadacimab biosimilar, Whole mAb, Anti-F12 Antibody: Anti-HAE3/HAEX/HAF therapeutic antibody |
| INN Name | Garadacimab |
| Target | F12 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG4 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | CSL Behring |
| Conditions Approved | na |
| Conditions Active | Hereditary angioedema;COVID-19 |
| Conditions Discontinued | na |
| Development Tech | na |
About target - F12
1. Protein Coagulation factor XII
2. Gene F12
3. Organism Homo sapiens (Human)
Function
Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then trypsin cleaves it to beta-factor XIIa. Alpha-factor XIIa activates factor XI to factor XIa.
Catalytic activity
Selective cleavage of Arg-|-Ile bonds in factor VII to form factor VIIa and factor XI to form factor XIa. EC:3.4.21.38
